Weiss Ratings Reaffirms “Sell (E+)” Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “sell (e+)” rating reissued by research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded Imunon from a “hold” rating to a “sell” rating in a research report on Friday, September 5th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $232.50.

Imunon Price Performance

NASDAQ:IMNN opened at $5.33 on Wednesday. The company has a market cap of $13.01 million, a P/E ratio of -0.41 and a beta of 2.22. The stock’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $11.39. Imunon has a 1 year low of $4.70 and a 1 year high of $41.22.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.